Current management of patients with nonalcoholic fatty liver disease. Issue 6 (November 2013)

• Record Type: Journal Article
• Authors: Elsheikh, Elzafir; Henry, Linda L; Younossi, Zobair M
• Is Part Of: Expert review of endocrinology & metabolism. Volume 8:Issue 6(2013)
• Page Start: 549
• Page End: 558
• Publication Date: 2013-11
• Subjects: CVD -- diabetes mellitus -- insulin sensitivity -- medical and surgical treatment interventions -- NAFLD -- NASH -- obesity -- weight loss; Endocrinology -- Periodicals; Metabolism -- Periodicals; 616.4
• DOI: 10.1586/17446651.2013.846212
• Languages: English
• ISSNs: 1744-6651

Abstract

Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH) are the most common causes of chronic liver disease in industrialized countries. NAFLD has also been strongly associated with type II diabetes and cardiovascular diseases. This study was a multipurposed review, which included discussion of recent studies investigating the cellular and genetic basis of these diseases, the pathogenesis of NAFLD and the current treatment and management of nonalcoholic steatohepatitis. Currently, maintaining a healthy weight through dietary changes and exercise, the use of insulin-modulating pharmacologic agents for diabetes control and the use of lipid-lowering, anti-oxidants have been the most widely recommended treatments. Inclusion of pathogenic mechanisms in treatment design will allow future therapies to target-specific pathways involved in NAFLD pathogenesis.